R&D channel feed

Re­gen­eron touts pos­i­tive pre­lim­i­nary im­pact of its Covid an­ti­body cock­tail, pre­vent­ing symp­to­matic in­fec­tions in high-risk group

5 years ago
Coronavirus

As­traZeneca's Calquence nabs an­oth­er win against Im­bru­vi­ca, but Eli Lil­ly is on its heels

5 years ago

Roche amps up its bis­pe­cif­ic at­tack on Eylea with more PhI­II da­ta — but just how threat­en­ing is it?

5 years ago

Fast on Glax­o­SmithK­line's heels, Au­rinia wins OK to steer a sec­ond lu­pus nephri­tis drug straight to the mar­ket

5 years ago

What does $29B buy you in Big Phar­ma? In Glax­o­SmithK­line’s case, a whole lot of un­com­fort­able ques­tions about the pipeline

5 years ago

Glax­o­SmithK­line scraps a LAG3 study, mark­ing an­oth­er fail­ure for the pipeline af­ter a crit­i­cal set­back

5 years ago

Months af­ter a ma­jor re­brand­ing around CAR-NKT cells, Ku­ur Ther­a­peu­tics is of­fer­ing a peek at ear­ly re­sults

5 years ago

Eli Lil­ly's an­ti­body cuts risk of Covid-19 by up to 80% among the most vul­ner­a­ble — but will it have a place next to vac­cines?

5 years ago
Coronavirus

With patent con­cerns loom­ing, Roche gets a new pri­or­i­ty re­view on block­buster IPF drug

5 years ago

Glax­o­SmithK­line's $4B bis­pe­cif­ic can­cer drug al­liance with Mer­ck KGaA hit by big set­back with a PhI­II fail­ure on NSCLC

5 years ago

Gilead part­ner Ar­cus earns an­a­lyst­s' plau­dits for ear­ly pan­cre­at­ic can­cer da­ta that 'ex­ceed­ed ex­pec­ta­tion­s'

5 years ago

Can Brett Mo­nia push Io­n­is be­yond Spin­raza?

5 years ago

R&D ex­ec faces up to 10 years in prison on charges he stole “thou­sands” of top se­cret re­search doc­u­ments from Mer­ck

5 years ago
People

A much-hyped CV drug failed, re­peat­ed­ly. Now, in­vestors are bet­ting near­ly $200M on one last PhI­II bid

5 years ago

#JPM21: Avid­i­ty CSO Art Levin runs full speed to the clin­ic with 'dream' an­ti­body oligonu­cleotide con­ju­gate ther­a­py

5 years ago

With KRAS break­through on the hori­zon, Am­gen's David Reese re­flects on so­tora­si­b's loom­ing re­view date and murky fu­ture

5 years ago
People

Vir and Gilead, two of the biggest names in the hunt for an HBV cure, team up for com­bi­na­tion tri­al

5 years ago

Look­ing to leapfrog an­ti­bod­ies and RNAi, Sekar Kathire­san says gene edit­ing ap­proach to cut PC­SK9 looks durable

5 years ago
Discovery

John Maraganore makes a bold promise ahead of #JPM21 — aim­ing to take Al­ny­lam in­to the ranks of biotech's best

5 years ago

Eli Lil­ly adds $23B in mar­ket cap as in­vestors rush on promise that this will be the amy­loid Alzheimer's drug that works

5 years ago

With mR­NA proof of con­cept on dis­play in Covid-19, Mod­er­na plots HIV vac­cine moon­shot as part of pipeline ex­pan­sion

5 years ago

Still reel­ing from re­jec­tion, Bio­Marin re­ports a glimpse of those 2-year val­rox da­ta FDA was look­ing for — but is it enough to change reg­u­la­tors' minds?

5 years ago
Cell/Gene Tx

FDA side­swipes Ne­oleukin with clin­i­cal hold on lead im­munother­a­py can­di­date, sends shares plum­met­ing

5 years ago
FDA+

Sarep­ta gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy fails on func­tion — rais­ing se­ri­ous ques­tions about all their drugs

5 years ago
First page Previous page 178179180181182183184 Next page Last page
A service from the Financial Times